Literature DB >> 19701675

Genetic susceptibility in solvent induced neurobehavioral effects.

L Godderis1, N Maertens, V de Gelder, A De Lamper, K De Ruyck, M Vernimmen, S Bulterys, G Moens, H Thierens, M K Viaene.   

Abstract

The aim of this investigation was to study the influence of genetic polymorphisms of biotransformation enzymes and dopamine receptors on neurobehavioral effects in referents (n = 53), solvent-workers (n = 144), and chronic toxic encephalopathy (CTE) patients (n = 33). All participants were interviewed for exposure data and confounding factors and underwent a clinical examination. Neurobehavioral complaints (neurotoxicity symptom checklist-60) and effects [simple reaction time (SRT), symbol digit substitution (SDS), hand-eye coordination (HEC), and digit span backwards (DSB)] were evaluated with a computer assisted test battery. The following genotypes were determined: GSTM1, GSTT1, GSTP1, DRD2 Taq1A, DRD2 Taq1B, and DRD2-141Cdel. Neurotoxic effects and complaints were significantly higher in CTE patients and were related to both duration and level of exposure. An equal distribution of genotypes was found between all groups. Logistic regression analysis revealed that GSTT1 was negatively associated with sleep and sensorimotor complaints. GSTM1 had a protecting influence on the relationship between logDSB and the cumulative exposure index and between logSRT and cumulative exposure index and degree of exposure, respectively. This effect was also found when correcting for age, education level, alcohol consumption, and smoking. DRD2-141Cdel polymorphisms had a negative influence on the relationship between logSDS and the total exposure time. GSTT1 might be protective against sleep and sensorimotor complaints, whereas GSTM1 seems to decrease sustained attention and short-term memory problems in relation to solvent exposure. Individuals possessing DRD2-141Cdel variant experienced more visuomotor problems.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19701675     DOI: 10.1007/s12640-009-9100-7

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  38 in total

1.  Interest of genotyping and phenotyping of drug-metabolizing enzymes for the interpretation of biological monitoring of exposure to styrene.

Authors:  Vincent Haufroid; Marek Jakubowski; Beata Janasik; Danuta Ligocka; Jean-Pierre Buchet; Enrico Bergamaschi; Paola Manini; Antonio Mutti; Sergio Ghittori; Michael Arand; Nina Hangen; Franz Oesch; Ari Hirvonen; Dominique Lison
Journal:  Pharmacogenetics       Date:  2002-12

2.  Analysis of the linkage of the Taq1A and Taq1B loci of the dopamine D2 receptor gene with schizophrenia in patients and their siblings.

Authors:  V E Golimbet; M G Aksenova; V V Nosikov; V A Orlova; V G Kaleda
Journal:  Neurosci Behav Physiol       Date:  2003-03

3.  Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease.

Authors:  Eng-King Tan; Yanni Tan; Anthea Chai; Christopher Tan; Hui Shen; Sau-Ying Lum; Stephanie M C Fook-Cheong; Mei-Ling Teoh; Yuan Yih; Meng-Cheong Wong; Yi Zhao
Journal:  Mov Disord       Date:  2003-05       Impact factor: 10.338

4.  Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.

Authors:  Caryn Lerman; Christopher Jepson; E Paul Wileyto; Leonard H Epstein; Margaret Rukstalis; Freda Patterson; Vyga Kaufmann; Stephanie Restine; Larry Hawk; Ray Niaura; Wade Berrettini
Journal:  Neuropsychopharmacology       Date:  2006-01       Impact factor: 7.853

Review 5.  Gene--environment interactions in the application of biomarkers of cancer susceptibility in epidemiology.

Authors:  S Garte; C Zocchetti; E Taioli
Journal:  IARC Sci Publ       Date:  1997

Review 6.  Solvents and neurotoxicity.

Authors:  R F White; S P Proctor
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

7.  Glutathione S-transferase M1 null genotype as a risk modifier for solvent-induced chronic toxic encephalopathy.

Authors:  P Söderkvist; A Ahmadi; A Akerbäck; O Axelson; U Flodin
Journal:  Scand J Work Environ Health       Date:  1996-10       Impact factor: 5.024

8.  Do organic solvents induce changes in the dopaminergic system? Positron emission tomography studies of occupationally exposed subjects.

Authors:  C Edling; B Hellman; B Arvidson; J Andersson; P Hartvig; A Lilja; S Valind; B Långström
Journal:  Int Arch Occup Environ Health       Date:  1997       Impact factor: 3.015

9.  Cadmium: a possible etiological factor in peripheral polyneuropathy.

Authors:  M K Viaene; H A Roels; J Leenders; M De Groof; L J Swerts; D Lison; R Masschelein
Journal:  Neurotoxicology       Date:  1999-02       Impact factor: 4.294

10.  Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure.

Authors:  G Hageman; J van der Hoek; M van Hout; G van der Laan; E J Steur; W de Bruin; K Herholz
Journal:  J Neurol       Date:  1999-03       Impact factor: 4.849

View more
  1 in total

1.  Chronic solvent-induced encephalopathy: course and prognostic factors of neuropsychological functioning.

Authors:  Evelien van Valen; Ellie Wekking; Moniek van Hout; Gert van der Laan; Gerard Hageman; Frank van Dijk; Angela de Boer; Mirjam Sprangers
Journal:  Int Arch Occup Environ Health       Date:  2018-06-25       Impact factor: 3.015

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.